A combination of bevacizumab and Zejula (niraparib) is significantly better than Zejula alone at extending the time without disease progression in people with platinum-sensitive relapsed ovarian cancer, findings from a clinical trial show. The combination also delayed the need for subsequent treatment by prolonging time without disease worsening, and showed a trend toward better survival rates, the researchers noted. These data were shared at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting — which was…
You must be logged in to read/download the full post.
The post Zejula-Bevacizumab Combo Delays Progression in Relapsed Ovarian Cancer, Trial Finds appeared first on BioNewsFeeds.